

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AK MEDICAL HOLDINGS LIMITED**

**愛康醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1789)**

**ANNOUNCEMENT  
PROFIT ALERT**

This announcement is made by AK Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the currently available preliminary assessment of the unaudited consolidated management accounts of the Company for the year ended 31 December 2022 (the “**Unaudited Management Accounts**”):

- (i) the Board expects to record an increase in revenue by over 35% for the year ended 31 December 2022 as compared to the revenue for the year ended 31 December 2021; and
- (ii) the Board expects to record a significant increase in net profit attributable to Shareholders by over 100% for the year ended 31 December 2022 as compared to the net profit attributable to Shareholders for the year ended 31 December 2021.

The increase in revenue for the year ended 31 December 2022 was primarily due to the strong demand of the Group’s products in hospitals caused by the speeding up of import substitution as a result of the implementation of volume-based procurement (the “**VBP**”) since April 2022 in China. Meanwhile, the extensive product lines of the Group, including 3D-printed products, have effectively met the needs of a differentiated market and further contributed to the growth of sales revenue.

The increase in net profit attributable to Shareholders for the year ended 31 December 2022 was primarily due to the increase in revenue as aforementioned, coupled with relatively stable costs and expenses by taking effective cost control measures.

As at the date of this announcement, the Company is still in the process of preparing the annual results of the Group for the year ended 31 December 2022 and is not able at this time disclose any further details on the above factors and their impact on the Group's net profit attributable to Shareholders. The information set out above is only based on a preliminary assessment by the Board with reference to the information currently available to it, including the Unaudited Management Accounts, which have not been finalized and have not been independently audited by the Company's auditors or reviewed by the audit committee of the Company. Shareholders and potential investors should refer to and review the annual results of the Company for the year ended 31 December 2022, which are expected to be published by the end of March 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**AK Medical Holdings Limited**  
**Li Zhijiang**  
*Chairman*

Hong Kong, 15 February 2023

*As at the date of this announcement, the executive Directors are Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong; the non-executive director is Dr. Wang David Guowei; and the independent non-executive directors are Mr. Kong Chi Mo, Dr. Li Shu Wing David and Mr. Eric Wang.*